Clinical Outcomes of CRISPR-Cas9 Mediated Gene Editing in Patients with Sickle Cell Disease A Biotechnology-Based Therapeutic Approach

Zahid Mehboob; Hashim Raza; Mahwish Riaz; Umm E Habiba

doi:10.62497/IRABCS.126

Authors

Zahid Mehboob The University of Lahore, 53700, Lahore, Pakistan Author
Muhammad Hashim Raza Government College University, Faisalabad, Pakistan Author
Mahwish Riaz Dr Yahya Institute of Medical Sciences, Layyah, Pakistan Author
Umm E Habiba University of Agriculture, Faisalabad, Pakistan Author

DOI:

https://doi.org/10.62497/IRABCS.126

Keywords:

CRISPR-Cas9, sickle cell disease, gene editing, hematopoietic stem cell transplantation, fetal hemoglobin, vaso-occlusive crises, gene therapy.

Abstract

Background
Sickle cell disease (SCD) is a severe monogenic disorder with limited curative options beyond allogeneic stem cell transplantation.

Objective
To evaluate the clinical efficacy and safety of CRISPR-Cas9 mediated gene editing in patients with SCD undergoing autologous hematopoietic stem cell transplantation.

Methodology
This prospective observational study was conducted at the Department of Hematology and Clinical Biotechnology, The University of Lahore, in collaboration with the National Institute for Genomics & Advanced Biotechnology (NIGAB), a division of the National Agricultural Research Centre (NARC), Islamabad, from April 2022 to March 2024. A total of 42 patients aged 12–40 years with homozygous SCD underwent autologous transplantation following CRISPR-Cas9 mediated editing of either the HBB gene or BCL11A erythroid enhancer. Clinical, hematologic, molecular, and immunologic outcomes were assessed at baseline, 12 months, and 24 months. Data analysis included paired t-tests and repeated measures ANOVA.

Results
The mean editing efficiency was 62.35% ± 9.42%. Hemoglobin levels improved from 7.42 ± 1.12 g/dL at baseline to 11.23 ± 1.07 g/dL at 24 months (p < 0.001), and reticulocyte counts decreased from 10.18 ± 2.45% to 3.94 ± 1.19% (p < 0.001). At 24 months, 92.31% achieved transfusion independence, 84.62% had a ≥90% reduction in vaso-occlusive crises, and 76.92% entered clinical remission. HbF levels >20% were maintained in 87.18% of patients, and sustained gene expression was observed in 94.87%. Multilineage hematopoietic reconstitution was confirmed via flow cytometry. No serious adverse events or deaths occurred during follow-up.

Conclusion
CRISPR-Cas9 gene editing shows high efficacy, safety, and potential as a transformative therapy for SCD.

Downloads

Download data is not yet available.

Author Biographies

Zahid Mehboob, The University of Lahore, 53700, Lahore, Pakistan

PhD Biochemistry

Institute of Molecular Biology and Biotechnology (IMBB Department)
Muhammad Hashim Raza, Government College University, Faisalabad, Pakistan

Institute of Microbiology
Mahwish Riaz, Dr Yahya Institute of Medical Sciences, Layyah, Pakistan

BS MLT
Umm E Habiba, University of Agriculture, Faisalabad, Pakistan

Department of Microbiology

References

Tebbi CK. Sickle cell disease, a review. Hemato. 2022 May 30;3(2):341-66. https://doi.org/10.3390/hemato3020024.

Inusa BP, Hsu LL, Kohli N, Patel A, Ominu-Evbota K, Anie KA, Atoyebi W. Sickle cell disease—genetics, pathophysiology, clinical presentation and treatment. International journal of neonatal screening. 2019 May 7;5(2):20. https://doi.org/10.3390/ijns5020020.

Matthews K, Lamoureux ES, Myrand-Lapierre ME, Duffy SP, Ma H. Technologies for measuring red blood cell deformability. Lab on a Chip. 2022;22(7):1254-74. https://doi.org/10.1039/D1LC01058A.

Patel S, Patel R, Mukkala SR, Akabari A. Emerging therapies and management approaches in sickle cell disease (SCD): A critical review. Journal of Phytonanotechnology and Pharmaceutical Sciences. 2023;3(3):1-1. DOI: http://dx.doi.org/10.54085/jpps.2023.3.3.6.

Kassim AA, Sharma D. Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape. Hematology/oncology and stem cell therapy. 2017 Oct 1;10(4):259-66. DOI: 10.1016/j.hemonc.2017.05.008.

Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020 Feb 13;578(7794):229-36. https://doi.org/10.1038/s41586-020-1978-5.

Li J, Tang C, Liang G, Tian H, Lai G, Wu Y, Liu S, Zhang W, Liu S, Shao H. Clustered regularly interspaced short palindromic repeats and clustered regularly Interspaced Short Palindromic Repeats–Associated protein 9 system: factors affecting Precision Gene Editing Efficiency and optimization strategies. Human Gene Therapy. 2023 Dec 1;34(23-24):1190-203.

https://doi.org/10.1089/hum.2023.115.

Tariq H, Khurshid F, Khan MH, Dilshad A, Zain A, Rasool W, Jawaid A, Kunwar D, Khanduja S, Akbar A. CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review. Annals of Medicine and Surgery. 2024 Oct 1;86(10):5938-46. DOI: 10.1097/MS9.0000000000002478.

Butt H, Sathish S, London E, Johnson TL, Essawi K, Leonard A, Tisdale JF, Demirci S. Genome Editing Strategies for Targeted Correction of β-globin Mutation in Sickle Cell Disease: From Bench to Bedside. Molecular Therapy. 2025 Mar 30. DOI:10.1016/j.ymthe.2025.03.047.

Battini S. Advancements in CRISPR-Cas9 Gene Editing: Applications and Future Implications for Sickle Cell Disease and β-Thalassemia Treatment. https://digitalcommons.lib.uconn.edu/srhonors_theses/999.

Butt H, Tisdale JF. Gene therapies on the horizon for sickle cell disease: a clinician’s perspective. Expert Review of Hematology. 2024 Sep 1;17(9):555-66. https://doi.org/10.1080/17474086.2024.2386366

Lessard S, Rimmelé P, Ling H, Moran K, Vieira B, Lin YD, Rajani GM, Hong V, Reik A, Boismenu R, Hsu B. Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease. Scientific reports. 2024 Oct 16;14(1):24298. https://doi.org/10.1038/s41598-024-74716-7.

Olatunya, O.S., Lanaro, C., Longhini, A.L. et al. Red blood cells microparticles are associated with hemolysis markers and may contribute to clinical events among sickle cell disease patients. Ann Hematol 98, 2507–2521 (2019). https://doi.org/10.1007/s00277-019-03792-x

Ahmed, R., Alghamdi, W.N., Alharbi, F.R. et al. CRISPR/Cas9 System as a Promising Therapy in Thalassemia and Sickle Cell Disease: A Systematic Review of Clinical Trials. Mol Biotechnol (2025). https://doi.org/10.1007/s12033-025-01368-x

Abdel-Hadi L, Carmenate YV, Castillo-Aleman YM, Sheikh S, Zakaria A, Phillips J. Treatment of sickle cell disease-options and perspective. American journal of blood research. 2023 Apr 15;13(2):61. https://pmc.ncbi.nlm.nih.gov/articles/PMC10195315/.

Zarghamian P, Klermund J, Cathomen T. Clinical genome editing to treat sickle cell disease—a brief update. Frontiers in Medicine. 2023 Jan 9;9:1065377. https://doi.org/10.3389/fmed.2022.1065377.

Tolu SS, Wang K, Yan Z, Zhang S, Roberts K, Crouch AS, Sebastian G, Chaitowitz M, Fornari ED, Schwechter EM, Uehlinger J. Characterization of hematopoiesis in sickle cell disease by prospective isolation of stem and progenitor cells. Cells. 2020 Sep 24;9(10):2159. https://doi.org/10.3390/cells9102159.

Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. New England Journal of Medicine. 2009 Dec 10;361(24):2309-17. DOI: 10.1056/NEJMoa0904971.